Sorafenib

>95% (TLC)

lyophilized powder

~464.8

ambient

−20℃

Clinically useful anticancer agent.

Initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-beta (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM) ⁽¹⁾. Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms ⁽²⁾. Inhibits activation of MAPK pathway and ERK phosphorylation ⁽³⁾. Induces caspase-independent apoptosis in melanoma cells ⁽⁴⁾.

Formulated as a lyophilized powder. May be dissolved in DMSO (200 mg/mL) or Ethanol (3 mg/mL).

Store desiccated as supplied at -20℃ for up to 2 years. Store solutions at -20℃ for up to 1 month.

GHS08,GHS09

Danger

H360FD - H362 - H372 - H410

P202 - P260 - P263 - P264 - P273 - P308 + P313

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK 3